Conference Calendar

March 14-18 - American Association of Orthopaedic Medicine Annual Meeting 2017

March 14-December 31 - Canaccord Genuity Musculoskeletal Conference

Complete Calendar »

Earnings Calendar

No Upcoming Events Scheduled
Complete Calendar »

Read our research via:
email art

Weekly Email

rss art


app icon


app store icon


Orthopedic and Dental Industry News

October 2004

Troubling Consistency at Sofamor Danek BY ROBIN R. YOUNG CFA, OCTOBER 25, 2004

Two whistle blower lawsuits in the last 13 months. Two court rulings in favor of Dr. Gary Michelson's claim that Sofamor Danek infringed his property rights. A court ordered permanent injunction against Sofamor Danek last month in a patent case.... more

The 3Q:04 Earnings Season is Half-way Completed for Large Joint Manufacturers: Any Trends? BY JOHN CHOPACK, OCTOBER 25, 2004

Three of the seven leading large joint orthopedic manufacturers have reported their 3Q:04 financials. So far, market growth rates on a constant currency basis remain in-line with the growth rates reported by industry leaders DePuy, Biomet and Stryker in the... more

Thirty Percent Sales Growth Highlights ArthroCare's Third Quarter Report BY JOHN MCCORMICK, OCTOBER 25, 2004

Last week, ArthroCare Corp (Nasdaq: ARTC) announced that for the third quarter ending September 30, revenues rose 30% on year-over-year (YOY) basis. Total revenues, which include product revenues, license fees and royalties, for 3Q:04 were $38.2 million versus the $29.4... more

Cartilage Repair Comes of Age: An Interview with Gerald 'Gary' Bisbee, CEO of ReGen Biologics, Inc. BY JOHN MCCORMICK, OCTOBER 25, 2004

Cartilage repair is coming of age. One of the leaders in this emerging technology is ReGen Biologics. During the recent HealthpointCapital Biologics Summit, we spent a few quality moments interviewing Gary Bisbee, CEO of ReGen Biologics. JM: Introduce our Readers... more

Ceramic-on-Ceramic Hip Arthroplasty: Impact on the Market BY JOHN CHOPACK, OCTOBER 25, 2004

Given that the first ceramic-on-ceramic hip arthroplasty approval came approximately a year and half ago, we thought it would be a good time to analyze its effect on the market to date and what we expect in the future. Although... more

Medicare (CMS) Adds Express Lane for New Orthopedic Technology BY ROBIN R. YOUNG CFA, OCTOBER 11, 2004

The Center for Medicare and Medicaid Services announced on October 6 that it is going to implement seven new and specific improvements which, in the aggregate, should speed up development of new technology codes as well as simplify coverage and... more

Appeals Court Deals Zimmer Setback BY ROBIN R. YOUNG CFA, OCTOBER 11, 2004

The U.S. Court of Appeals for the Third Circuit (Pennsylvania and New Jersey) breathed new life last week into an otherwise moribund case against Zimmer. In remanding the case back to a lower court, which had dismissed it earlier, the... more

dj Orthopedics Announces Revenue Shortfall and Stock Repurchase BY JOHN MCCORMICK, OCTOBER 4, 2004

Last week, dj Orthopedics (NYSE: DJO) stock fell 10% on the announcement that it was cutting its third quarter outlook. The shortfall largely comes from previously announced integration efforts associated with the Company's Regentek unit, which manufactures bone growth stimulation... more

VIOXX: Systemic Problems Doom Another Systemic Drug BY ROBIN R. YOUNG CFA, OCTOBER 4, 2004

Since its introduction, more than 91 million prescriptions for VIOXX have been written in the United States for patients with arthritis pain in either the hip or knee. If one were to include all the prescription Cox-2 inhibitor drugs like... more

Spine Wars: Michelson vs. the Industry? BY ROBIN R. YOUNG CFA, OCTOBER 4, 2004

If we've heard it once, we've heard it a dozen times. Gary Michelson, with attorneys in tow, haunts spine company booths at conferences like the upcoming NASS or CNS informing them of patent violations on the fly. Yikes! And last... more


In our article last week summarizing the excellent State and Future of the Orthopaedic Industry conference in Chicago last week, we made the following errors: We stated in our table that Recon sales rose 38% to $7.5 billion. We were... more

Complete Archive